Track topics on Twitter Track topics that are important to you
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Depomed, Inc. (“Depomed” or the “Company”) (NASDAQ: DEPO) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Depomed investigation page on our website at http://www.glancylaw.com/case/depomed-inc.
On August 7, 2017, Demoped announced that it had received a request for information relating to the promotion of opioids from the U.S. Senate Committee on Homeland Security and Governmental Affairsas well as the Office of the Attorney General of Maryland and the U.S. Department of justice.
On this news, the Company’s stock price fell sharply in after-hours trading.
If you purchased Depomed securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.